Alternative Pneumocystis Pneumonia Prophylaxis in Solid Organ Transplants
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.14410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Kevin D He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Organ Transplantation, Atovaquone, Dapsone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Despite limited data supporting use in solid organ transplant (SOT) recipients, atovaquone and dapsone are often used as alternatives to trimethoprim‐sulfamethoxazole (TMP‐SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis.
Methods
This single‐center, retrospective cohort study describes a multi‐organ program's experience with alternative PJP prophylaxis. Adult SOT recipients transplanted November 13, 2020 to November 13, 2022 who received non‐TMP‐SMX PJP prophylaxis and had > 1 year follow‐up were included.
Results
Among 953 SOTs performed, 333 (34.9%) recipients received alternative PJP prophylaxis (319 [95.8%] atovaquone and 14 [4.2%] dapsone). Alternative prophylaxis was initiated in 76 (22.8%) recipients without starting TMP‐SMX, mostly due to sulfa allergy (62, 81.6%). In 257 recipients who started TMP‐SMX, common reasons for switching to alternatives were hyperkalemia (105, 40.9%) and leukopenia (77, 30.0%). While 79.8% of recipients had these adverse effects resolve, only 27.3% resumed TMP‐SMX. Tolerance was high after resumption (85.7%). Barriers to accessing alternative prophylaxis included cost (25, 7.5%) and prior authorizations (26, 7.8%). There was one case of severe disseminated toxoplasmosis, one case of Nocardia infection, and no cases of PJP.
Conclusion
Alternative PJP prophylaxis carries risk of breakthrough infection and barriers to initiation. Since most recovered from adverse effects of TMP‐SMX and tolerated resumption, providers should re‐trial TMP‐SMX when feasible. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Renal Electrolyte and Hypertension, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Transplant Surgery, Department of Surgery, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Kevin D He, Linh Nguyen, Maxwell Norris, Gregory Malat, Stephanie Witek, Chelsea Sammons, Abigail Forte, Tamara Claridge, Jennifer Trofe Clark, Emily Blumberg
Zitieren
APA
He, K. D., Nguyen, L., Norris, M., Malat, G., Witek, S., Sammons, C., Forte, A., Claridge, T., Clark, J. T., & Blumberg, E. (2025). Alternative Pneumocystis Pneumonia Prophylaxis in Solid Organ Transplants. Transplant Infectious Disease. https://doi.org/10.1111/tid.14410
Vancouver
He KD, Nguyen L, Norris M, Malat G, Witek S, Sammons C, et al. Alternative Pneumocystis Pneumonia Prophylaxis in Solid Organ Transplants. Transplant Infectious Disease. 2025. doi:10.1111/tid.14410
BibTeX
@article{He2025,
author = {He, Kevin D and Nguyen, Linh and Norris, Maxwell and Malat, Gregory and Witek, Stephanie and Sammons, Chelsea and Forte, Abigail and Claridge, Tamara and Clark, Jennifer Trofe and Blumberg, Emily},
title = {Alternative Pneumocystis Pneumonia Prophylaxis in Solid Organ Transplants},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.14410}
}
EUVIMED